Author Interviews, Breast Cancer, Brigham & Women's - Harvard, JAMA, Surgical Research / 08.01.2020
Despite Better Chemotherapy, US Women Choosing More Rather Than Less TNBC Surgery
MedicalResearch.com Interview with:
Mehra Golshan, MD, MBA
Dr. Abdul Mohsen & Sultana Al-Tuwaijri Distinguished Chair
Surgical OncologyDirector of Breast Surgical Oncology Fellowship
Associate Professor, Harvard Medical School
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Triple negative breast cancer is an aggressive form of breast cancer that often requires chemotherapy. In this study we provided neoadjuvant chemotherapy with or without a PARP inhibitor and showed that many women who were originally ineligible for breast conservation (lumpectomy) became eligible after treatment.
If lumpectomy was tried it was usually successful. Many more women in the US compared to Europe and Asia chose mastectomy when lumpectomy was an option even when genetics is negative.
(more…)